An Original Investigation on Pharmacy and Clinical Pharmacology published in JAMA Network Open concluded that In type 2 diabetes patients using GLP-1RA medication, there was no evidence supporting increased pancreatic cancer risk after seven years. However, continued monitoring beyond this period is still necessary.
In this study, adult patients with type 2 diabetes insured by Clalit Healthcare Services in Israel were followed from 2009 to 2017. The exposure was treatment with GLP-1RA compared to basal insulin.
In a Cox model, pancreatic cancer incidence was compared based on weighted cumulative exposure to GLP-1RA and basal insulin, adjusting for confounding variables with a time origin at two years after diabetes diagnosis. Sensitivity analyses were conducted using propensity score-matched and prevalent new-user designs, emphasising results from the fifth to seventh year after medication.
The results of this study are:
· During a cumulative follow-up of 3 290 439 person-years of 543 595 adults with a mean age of 59.9 years with incident diabetes, 1665 patients received pancreatic cancer diagnoses.
· 33 377 patients, constituting 6.1%, used GLP-1RA, and 106 849, constituting 19.7%, used basal insulin.
· The estimated hazard ratio (HR) for pancreatic cancer associated with incremental use of 1 defined daily dose per day of GLP-1RA in comparison to basal insulin in the fifth to seventh year previously was 0.50.
· The HR for new-user and prevalent new-user designs from the fifth year onwards after initiation of GLP-1RA vs basal insulin of 0.52 and 0.75, respectively.
Study strengths include the inclusion of a high-quality Clalit database and the high validity of the findings.
Our study did not show an increased risk of pancreatic cancer with the use of GLP-1RA in a cohort of over 500,000 adults with diabetes, they said.
Reference:
Dankner R et al. Glucagon-Like Peptide-1 Receptor Agonists and Pancreatic Cancer Risk in Patients With Type 2 Diabetes. JAMA Netw Open. 2024;7(1):e2350408. doi:10.1001/jamanetworkopen.2023.50408
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.